New England Journal of Medicine Publishes Positive Bladder Cancer Treatment Results

A significant study published in The New England Journal of Medicine details improved outcomes for muscle-invasive bladder cancer patients treated with a combination of enfortumab vedotin and pembrolizumab. The KEYNOTE-B15/EV-304 trial data showed enhanced event-free survival, overall survival, and pathological complete response rates compared to standard chemotherapy. This publication reinforces the regimen's efficacy, following its FDA approval for all MIBC patients earlier in July 2026.